ClinicalTrials.gg
TerminatedNCT03203369ABC123Updated Jul 31, 2019

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

A Phase 1 interventional study of UCART123 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), sponsored by Cellectis S.A.. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by Cellectis S.A. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States — 8 open to participants now, 13 under way, none of them phase 3. Blastic Plasmacytoid Dendritic Cell Neoplasm · United States.

Enrollment
30th of 31
1 · median 45
Started
2017
with 3 others
Phase 1
15 of 33
4 open now
Registered
12th of 33
by date
Lead sponsor
1 of 33
Cellectis S.A.

Among the 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States, this one is the 30th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2017, is one of 15 in phase 1, and was the 12th registered.

Blastic Plasmacytoid Dendritic Cell Neoplasm

45 studies on the registry are indexed under Blastic Plasmacytoid Dendritic Cell Neoplasm; 14 are open to participants now.

Browse Blastic Plasmacytoid Dendritic Cell Neoplasm studies →

Open to participants now

8 of the 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Blastic Plasmacytoid Dendritic Cell Neoplasm studies recruiting now, 7 (54%) set no upper age limit and 6 (46%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.

03

Conditions studied

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Keywords

  • Blastic plasmacytoid dendritic cell neoplasm
  • Natural Killer (NK) cell blastic lymphoma
  • Hematologic malignancies
  • Cluster of differentiation (CD) CD4+CD56+ hematodermic tumor
  • Acute leukemia and myeloid neoplasms
  • Chimeric Antigen Receptor T-cell (CAR-T) therapy
  • Allogeneic
  • Cluster of differentiation 4 (CD4)
  • Cluster of differentiation 56 (CD56)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Patients with a diagnosis BPDCN according to World Health Organization (WHO) classification confirmed by hematopathology;
  • (ECOG) Performance Status of 0 or 1;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation

    A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10\^5 cells/kg to 6.25 x 10\^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.

    Biological: UCART123

  • Experimental
    Part 2: Dose Expansion

    A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.

    Biological: UCART123

Interventions

  • BiologicalUCART123

    Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.

06

What researchers measure

Primary outcomes

  1. Incidence, nature, and severity of adverse events and serious adverse events

    Time frame: Through day 84

07

Study locations

1 site
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jun 2019, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2017
First posted
Jun 29, 2017
StartActual
Jun 28, 2017
Primary completionActual
Jun 27, 2019
CompletionActual
Jun 27, 2019
Last update
Jul 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03203369
Lead sponsor
Cellectis S.A.
Responsible party
Sponsor
First posted
Jun 29, 2017
Start date
Jun 28, 2017
Primary completion
Jun 27, 2019
Completion
Jun 27, 2019
Last update
Jul 31, 2019

Study contacts

Ioana Kloos, MD
study director · Cellectis S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion